Home LiteratureArticle Details
PMID: 26389673 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

The Journal of clinical investigation ·Vol. 125 ·No. 10 ·2015-10-01 ·Pages 3981-91

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF

Abstract

Adoptively transferred tumor-infiltrating T lymphocytes (TILs) that mediate complete regression of metastatic melanoma have been shown to recognize mutated epitopes expressed by autologous tumors. Here, in an attempt to develop a strategy for facilitating the isolation, expansion, and study of mutated antigen-specific T cells, we performed whole-exome sequencing on matched tumor and normal DNA isolated from 8 patients with metastatic melanoma. Candidate mutated epitopes were identified using a peptide-MHC-binding algorithm, and these epitopes were synthesized and used to generate panels of MHC tetramers that were evaluated for binding to tumor digests and cultured TILs used for the treatment of patients. This strategy resulted in the identification of 9 mutated epitopes from 5 of the 8 patients tested. Cells reactive with 8 of the 9 epitopes could be isolated from autologous peripheral blood, where they were detected at frequencies that were estimated to range between 0.4% and 0.002%. To the best of our knowledge, this represents the first demonstration of the successful isolation of mutation-reactive T cells from patients' peripheral blood prior to immune therapy, potentially providing the basis for designing personalized immunotherapies to treat patients with advanced cancer.

MeSH Terms
Adolescent Adult Algorithms Amino Acid Sequence Antigen-Antibody Reactions Antigens, Neoplasm/classification,genetics,immunology Cells, Cultured DNA, Neoplasm/genetics DNA-Binding Proteins/genetics,immunology Epitopes/genetics,immunology Exome Female Genes, erbB-2 HLA-A1 Antigen/chemistry,immunology HLA-A2 Antigen/chemistry,immunology Humans Interferon-gamma Release Tests Lymphocytes, Tumor-Infiltrating/immunology Male Melanoma/genetics,immunology,secondary Middle Aged Molecular Sequence Data Mutation Neoplasm Proteins/genetics,immunology Nuclear Proteins/genetics,immunology Peptide Fragments/immunology RNA, Neoplasm/genetics Receptor, ErbB-2/immunology T-Cell Antigen Receptor Specificity T-Lymphocytes/immunology TEA Domain Transcription Factors Transcription Factors/genetics,immunology
Chemicals
Antigens, Neoplasm DNA, Neoplasm DNA-Binding Proteins Epitopes HLA-A*02:01 antigen HLA-A1 Antigen HLA-A2 Antigen Neoplasm Proteins Nuclear Proteins Peptide Fragments RNA, Neoplasm TEA Domain Transcription Factors TEAD1 protein, human Transcription Factors ERBB2 protein, human Receptor, ErbB-2
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Cohen Cyrille J
Gartner Jared J
Horovitz-Fried Miryam
Shamalov Katerina
Trebska-McGowan Kasia
Bliskovsky Valery V
Parkhurst Maria R
Ankri Chen
Prickett Todd D
Crystal Jessica S
Li Yong F
El-Gamil Mona
Rosenberg Steven A
Robbins Paul F
References (50)
50 references, click to expand
  1. Adoptive immunotherapy of cancer using CD4(+) T cells.
    Curr Opin Immunol. 2009 Apr;21(2):200-8 PMID: 19285848
  2. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange.
    Nat Protoc. 2006;1(3):1120-32 PMID: 17406393
  3. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Nature. 2015 Apr 30;520(7549):692-6 PMID: 25901682
  4. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
    Clin Cancer Res. 2014 Jul 1;20(13):3401-10 PMID: 24987109
  5. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences.
    Cold Spring Harb Protoc. 2011 Jun;2011(6):695-715 PMID: 21632778
  6. Delving into somatic variation in sporadic melanoma.
    Pigment Cell Melanoma Res. 2012 Mar;25(2):155-70 PMID: 22260482
  7. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
    Mol Ther. 2011 Mar;19(3):620-6 PMID: 21157437
  8. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Science. 2015 Apr 3;348(6230):124-8 PMID: 25765070
  9. Immune Checkpoint Blockade in Cancer Therapy.
    J Clin Oncol. 2015 Jun 10;33(17):1974-82 PMID: 25605845
  10. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
    Science. 2014 May 9;344(6184):641-5 PMID: 24812403
  11. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
    Cancer Res. 1999 Dec 15;59(24):6230-8 PMID: 10626817
  12. Design and use of conditional MHC class I ligands.
    Nat Med. 2006 Feb;12(2):246-51 PMID: 16462803
  13. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
    N Engl J Med. 2008 Jun 19;358(25):2698-703 PMID: 18565862
  14. Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.
    Nat Biotechnol. 2013 Jul;31(7):623-9 PMID: 23748502
  15. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.
    J Immunol. 2013 Jun 15;190(12):6034-42 PMID: 23690473
  16. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
    Clin Cancer Res. 2011 Jul 1;17(13):4550-7 PMID: 21498393
  17. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
    J Immunol Methods. 1987 Aug 24;102(1):127-41 PMID: 3305708
  18. Selected murine residues endow human TCR with enhanced tumor recognition.
    J Immunol. 2010 Jun 1;184(11):6232-41 PMID: 20427762
  19. The cancer antigenome.
    EMBO J. 2013 Jan 23;32(2):194-203 PMID: 23258224
  20. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
    J Immunol. 2005 Nov 1;175(9):5799-808 PMID: 16237072
  21. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
    Sci Transl Med. 2014 Sep 17;6(254):254ra128 PMID: 25232180
  22. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers.
    J Immunol Methods. 2009 Jan 1;340(1):11-24 PMID: 18929568
  23. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  24. Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity.
    J Immunol. 2012 Jun 1;188(11):5538-46 PMID: 22544927
  25. Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment.
    Nat Rev Clin Oncol. 2014 Nov;11(11):630-2 PMID: 25311350
  26. T-cell epitope prediction methods: an overview.
    Methods Mol Biol. 2014;1184:333-64 PMID: 25048134
  27. A landscape of driver mutations in melanoma.
    Cell. 2012 Jul 20;150(2):251-63 PMID: 22817889
  28. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.
    Gene Ther. 2009 Aug;16(8):1042-9 PMID: 19494842
  29. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
    Nat Med. 2015 Jan;21(1):81-5 PMID: 25531942
  30. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
    Nat Med. 2013 Jun;19(6):747-52 PMID: 23644516
  31. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
    Science. 1992 Jul 10;257(5067):238-41 PMID: 1352912
  32. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
    Immunity. 2005 Jan;22(1):117-29 PMID: 15664164
  33. Properties of MHC class I presented peptides that enhance immunogenicity.
    PLoS Comput Biol. 2013 Oct;9(10):e1003266 PMID: 24204222
  34. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.
    Nature. 2014 Nov 27;515(7528):572-6 PMID: 25428506
  35. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
    Mol Ther. 2006 Jan;13(1):151-9 PMID: 16140584
  36. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  37. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    N Engl J Med. 2014 Dec 4;371(23):2189-99 PMID: 25409260
  38. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
    J Immunol. 2002 May 1;168(9):4802-8 PMID: 11971032
  39. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
    Nat Rev Cancer. 2014 Feb;14(2):135-46 PMID: 24457417
  40. Targeting cancer-specific mutations by T cell receptor gene therapy.
    Curr Opin Immunol. 2015 Apr;33:112-9 PMID: 25728991
  41. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.
    Oncoimmunology. 2014 May 14;3:e28836 PMID: 25083320
  42. CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.
    Int J Cancer. 2000 Jan 15;85(2):253-9 PMID: 10629086
  43. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
    J Clin Oncol. 2013 Nov 10;31(32):e439-42 PMID: 24043743
  44. Mutational landscape and significance across 12 major cancer types.
    Nature. 2013 Oct 17;502(7471):333-9 PMID: 24132290
  45. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
    Nature. 2014 Nov 27;515(7528):577-81 PMID: 25428507
  46. Immune epitope database analysis resource.
    Nucleic Acids Res. 2012 Jul;40(Web Server issue):W525-30 PMID: 22610854
  47. Cancer genome landscapes.
    Science. 2013 Mar 29;339(6127):1546-58 PMID: 23539594
  48. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
    Front Immunol. 2014 May 16;5:206 PMID: 24904570
  49. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
    Blood. 2009 Jul 16;114(3):535-46 PMID: 19451549
  50. Higher throughput methods of identifying T cell epitopes for studying outcomes of altered antigen processing and presentation.
    Front Immunol. 2013 Dec 05;4:430 PMID: 24367368
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
Published
2015-10-01
Epub
2015-00-21
Pages
3981-91
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC4607110
Subset
IM
Grants
NIAID NIH HHS · HHSN272201300006C · United States
PHS HHS · HHSN272201300006C · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com